ATOSSA THERAPEUTICS, INC.: cashflow_financing
| Value | {"amount": 102428000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2021-01-01 – 2021-03-31 |
| Status | current |
| Entity | ATOSSA THERAPEUTICS, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T14:48:04.568110+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/69a9b8cf-d2c2-4171-8d82-da250c8ad808
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001437749-22-011508 · Open the official SEC filing →Retrieved: 2026-08-19T14:48:04.568110+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001488039/cashflow-financing/2021-03-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/69a9b8cf-d2c2-4171-8d82-da250c8ad808
History
- supersedes {"amount": 102428710, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} (evidence 0001437749-21-012213)